AGRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Agile Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017

NEW YORK, Feb. 22, 2017

Click here to learn about the case: http://www.wongesq.com/pslra/agile-therapeutics-inc. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, Agile Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (a) the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (b) over half of patients in its "Secure" Phase 3 Study discontinued the study early; and (c) the Twirla patch therefore allegedly had a slight chance of gaining approval by the U.S. Food and Drug Administration.

On January 3, 2017, Agile Therapeutics reported "positive top-line results" for the study, yet reported an efficacy measure that failed to meet the standard set by other approved contraceptive patches. In addition, more than 51% of subjects opted to discontinue the study. Upon this news, shares of Agile Therapeutics fell from a close of $5.70 per share on December 30, 2016, to a close of $2.63 per share on January 4, 2017.

If you suffered a loss in Agile Therapeutics you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/agile-therapeutics-inc.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.